Details
Stereochemistry | ACHIRAL |
Molecular Formula | C31H24F2N4O3 |
Molecular Weight | 538.5441 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=O)C1=C(OC2=C1C(F)=C(C=C2)C3=CC(=CC=C3C)C(=O)NC4(CC4)C5=NC=CC=N5)C6=CC=C(F)C=C6
InChI
InChIKey=LZAUGCMVNLZVJV-UHFFFAOYSA-N
InChI=1S/C31H24F2N4O3/c1-17-4-5-19(28(38)37-31(12-13-31)30-35-14-3-15-36-30)16-22(17)21-10-11-23-24(26(21)33)25(29(39)34-2)27(40-23)18-6-8-20(32)9-7-18/h3-11,14-16H,12-13H2,1-2H3,(H,34,39)(H,37,38)
Bristol-Myers Squibb developed BMS-929075 as a selective, orally bioavailable hepatitis C virus (HCV) NS5B polymerase inhibitor for the treatment of chronic HCV infection. BMS-929075 was involved in phase I clinical trials for hepatitis C virus (HCV) infected patients; however, the company withdrew a study prior to enrolment.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01525212
Oral Suspension, ≤ 25 mg, Once daily, 3 days; Oral Suspension, ≤ 100 mg, Once daily, 3 days; Oral Suspension, ≤ 400 mg, Once daily, 3 days
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
59275404
Created by
admin on Sat Dec 16 11:39:44 GMT 2023 , Edited by admin on Sat Dec 16 11:39:44 GMT 2023
|
PRIMARY | |||
|
DB14950
Created by
admin on Sat Dec 16 11:39:44 GMT 2023 , Edited by admin on Sat Dec 16 11:39:44 GMT 2023
|
PRIMARY | |||
|
8S38482CST
Created by
admin on Sat Dec 16 11:39:44 GMT 2023 , Edited by admin on Sat Dec 16 11:39:44 GMT 2023
|
PRIMARY | |||
|
1217338-97-0
Created by
admin on Sat Dec 16 11:39:44 GMT 2023 , Edited by admin on Sat Dec 16 11:39:44 GMT 2023
|
PRIMARY |
ACTIVE MOIETY